Gemzar Gets Treatment IND for Advanced Pancreatic Cancer

April 1, 1995

INDIANAPOLIS--Eli Lilly and Company has received FDA approval to provide gemcitabine (Gemzar) to advanced pancreatic cancer patients through a Treatment Investigational New Drug program.

INDIANAPOLIS--Eli Lilly and Company has received FDA approvalto provide gemcitabine (Gemzar) to advanced pancreatic cancerpatients through a Treatment Investigational New Drug program.

The agent will be provided free of charge to patients who arenot candidates for surgery and who meet certain medical eligibilitycriteria. Patients may have been previously untreated or havehad one prior chemotherapy regimen. Physicians may call 1-800-621-7111for more information about the Treatment IND.